TargetBeta
HMGCR
3-hydroxy-3-methylglutaryl-CoA reductase · Oxidoreductases
4 programs in company-led studies act on HMGCR, from 4 companies: 0 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| rosuvastatinrule | AstraZeneca | phase 4 | 1849 running | – | ChEMBL |
| Atorvastatinrule | Viatris | phase 4 | 1865 running | – | ChEMBL |
| pitavastatinrule | Kowa | phase 4 | 362 running | – | ChEMBL |
| Simvastatinrule | Organon | phase 4 | 1001 running | – | ChEMBL |
Conditions their studies are in
- Hypercholesterolemia, 4 programs
- Hyperlipidemias, 4 programs
- Diabetes Mellitus, Type 2, 3 programs
- Dyslipidemias, 3 programs
- Cardiovascular Diseases, 2 programs
- Hypertension, 2 programs
- Coronary Artery Disease, 1 program
- Renal Insufficiency, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026pitavastatin · Kowa · phase 4 · NCT07726368
- Dec 1, 2026Atorvastatin · Viatris · phase 4 · NCT06974084
- Dec 5, 2026rosuvastatin · AstraZeneca · phase 4 · NCT07550816
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.